Covaxin Trial At AIIMS: 20 Per Cent Participants Ineligible

Over 20% of the participants who were screened for Bharat Biotech's Covaxin trials at AIIMS, Delhi cannot be administered the vaccine as they have already developed antibodies for COVID-19, reported The Indian Express.

From the 3500 who applied for the trials, the apex hospital screened 80 participants, but only 16 have been recruited for the trial so far. Only one person has been administered the vaccine who has not developed any discomfort in a week after administration. In the screening, 1 in 5 had developed antibodies while a few others had other health issues which made them unfit for the trial. AIIMS has to recruit over 100 participants for the trial.